JOIN THE PHYSIONIC INSIDERS [PREMIUM CONTENT]
Join the Physionic Insiders: https://bit.ly/PhysionicInsiders2

HEALTH AUTONOMY [COURSE]
Learn to Analyze & Apply Studies for Yourself: https://bit.ly/healthautonomy

JOIN THE COMMUNITY
Join my Community [It’s Free!]: https://bit.ly/PhysionicCommunity2

EMAIL LIST
1-2 Weekly Email of Value [It’s Free!]: http://bit.ly/2AXIzK6

HIRE ME FOR CONSULTING:
Consulting: https://bit.ly/3dmUl2H

Created with Biorender

0:00 - Introduction
0:30 - A Peptide for my Liver, Please
1:49 - I’ll Keep my Weight, though
3:49 - An Unlikely Alliance

Other videos on Peptides:
Osteoarthritis: https://www.youtube.com/watch?v=72rzR4Qo3zo
The Most Potent Peptide: https://www.youtube.com/watch?v=T9KJ8HGRmwM
Visceral Fat Specific: https://www.youtube.com/watch?v=m5BcB5_dWic

References
[Study 799] Gonzalez-Rellan MJ, Riobello C, Fang S, et al. The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors. Cell Metab. Published online 2026. doi:10.1016/j.cmet.2026.03.011

Funding/Conflicts: Public Funding: From the study, the work was funded by grants from the Canadian Institutes of Health Research; Non-Profit Funding: From the study, funding also came from a Sinai Health–Novo Nordisk Foundation Fund in Regulatory Peptides; Industry Funding: From the study, no direct industry funding source was reported, but D.J.D. disclosed consulting fees from Amgen, AstraZeneca, Crinetics, Eli Lilly, and other companies, and Mount Sinai Hospital has received investigator-initiated grant support from industry sponsors for preclinical studies in the Drucker lab.

[Study 800] Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384(12):1113-1124. doi:10.1056/NEJMoa2028395

Funding/Conflicts: Public Funding: From the study, no public funding source was reported; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, the trial was funded by Novo Nordisk, and conflicts included multiple authors being employees of Novo Nordisk, holding Novo Nordisk stock, or receiving advisory, consulting, lecture, travel, research, or grant support from Novo Nordisk and other pharmaceutical companies; the authors stated no other potential conflict of interest relevant to the article was reported.

[Study 801] Sanyal AJ, Newsome PN, Kliers I, Harms Østergaard L, Long MT, Kjær MS, et al. Phase 3 trial of semaglutide in metabolic dysfunction–associated steatohepatitis. N Engl J Med. 2025;392(21):2089-2099. doi:10.1056/NEJMoa2413258

Funding/Conflicts: Public Funding: From the study, no public funding source was reported; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, the trial was funded/supported by Novo Nordisk, and the paper stated that author disclosure forms were available with the full article; several listed author affiliations were with Novo Nordisk.

[Study 802] Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, et al. Semaglutide 2.4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(6):511-522. doi:10.1016/S2468-1253(23)00068-7

Funding/Conflicts: Public Funding: From the study, no public funding source was reported; Non-Profit Funding: From the study, no non-profit funding source was reported; Industry Funding: From the study, the trial was funded by Novo Nordisk A/S, and conflicts included author relationships with Novo Nordisk and other pharmaceutical companies, with the paper noting disclosure forms were provided by the authors.

Please use the following link to submit your critique: https://bit.ly/PhysionicCritique

Disclaimer: None of the information provided by this brand is a replacement for your physician's advice. This brand is information for the sake of knowledge and the options of choice it provides, not in any way a personalized prescription. Please consult your physician before making any health related changes.